The CYP2C19*17 variant is not independently associated with clopidogrel response

Authors

  • J. P. Lewis,

    1. Division of Endocrinology, Diabetes, and Nutrition and Program in Personalized and Genomic Medicine, School of Medicine, University of Maryland, Baltimore, MD, USA
    Search for more papers by this author
    • These authors have contributed equally to this work.
  • S. H. Stephens,

    1. Division of Endocrinology, Diabetes, and Nutrition and Program in Personalized and Genomic Medicine, School of Medicine, University of Maryland, Baltimore, MD, USA
    Search for more papers by this author
    • These authors have contributed equally to this work.
  • R. B. Horenstein,

    1. Division of Endocrinology, Diabetes, and Nutrition and Program in Personalized and Genomic Medicine, School of Medicine, University of Maryland, Baltimore, MD, USA
    Search for more papers by this author
  • J. R. O'Connell,

    1. Division of Endocrinology, Diabetes, and Nutrition and Program in Personalized and Genomic Medicine, School of Medicine, University of Maryland, Baltimore, MD, USA
    Search for more papers by this author
  • K. Ryan,

    1. Division of Endocrinology, Diabetes, and Nutrition and Program in Personalized and Genomic Medicine, School of Medicine, University of Maryland, Baltimore, MD, USA
    Search for more papers by this author
  • C. J. Peer,

    1. Clinical Pharmacology Program, National Cancer Institute, Bethesda, MD, USA
    Search for more papers by this author
  • W. D. Figg,

    1. Clinical Pharmacology Program, National Cancer Institute, Bethesda, MD, USA
    Search for more papers by this author
  • S. D. Spencer,

    1. Applied and Developmental Research, SAIC-Frederick Inc., National Cancer Institute, Frederick, MD, USA
    Search for more papers by this author
  • M. A. Pacanowski,

    1. U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Clinical Pharmacology, Silver Spring, MD, USA
    Search for more papers by this author
  • B. D. Mitchell,

    1. Division of Endocrinology, Diabetes, and Nutrition and Program in Personalized and Genomic Medicine, School of Medicine, University of Maryland, Baltimore, MD, USA
    Search for more papers by this author
  • A. R. Shuldiner

    Corresponding author
    1. Division of Endocrinology, Diabetes, and Nutrition and Program in Personalized and Genomic Medicine, School of Medicine, University of Maryland, Baltimore, MD, USA
    2. Geriatric Research and Education Clinical Center, Veterans Administration Medical Center, Baltimore, MD, USA
    • Correspondence: Alan R. Shuldiner, School of Medicine, University of Maryland, 685 West Baltimore Street, Rm. 379, Baltimore, MD 21201, USA.

      Tel.: +1 410 706 1623; fax: +1 410 706 1622.

      E-mail: ashuldin@medicine.umaryland.edu

    Search for more papers by this author

  • Manuscript handled by: M. Cattaneo
  • Final decision: P. H. Reitsma, 4 June 2013

Summary

Background

Cytochrome P450 2C19 (CYP2C19) is the principal enzyme responsible for converting clopidogrel into its active metabolite, and common genetic variants have been identified, most notably CYP2C19*2 and CYP2C19*17, that are believed to alter its activity and expression, respectively.

Objective

We evaluated whether the consequences of the CYP2C19*2 and CYP2C19*17 variants on clopidogrel response were independent of each other or genetically linked through linkage disequilibrium (LD).

Patients/Methods

We genotyped the CYP2C19*2 and CYP2C19*17 variants in 621 members of the Pharmacogenomics of Anti-Platelet Intervention (PAPI) Study and evaluated the effects of these polymorphisms singly and then jointly, taking into account LD, on clopidogrel prodrug level, clopidogrel active metabolite level, and adenosine 5′-diphosphate (ADP)-stimulated platelet aggregation before and after clopidogrel exposure.

Results

The CYP2C19*2 and CYP2C19*17 variants were in LD (|D′| = 1.0; r2 = 0.07). In association analyses that did and did not account for the effects of CYP2C19*17, CYP2C19*2 was strongly associated with levels of clopidogrel active metabolite (β = −5.24, P = 3.0 × 10−9 and β = −5.36, P = 3.3 × 10−14, respectively) and posttreatment ADP-stimulated platelet aggregation (β = 7.55, P = 2.9 × 10−16 and β = 7.51, P = 7.0 × 10−15, respectively). In contrast, CYP2C19*17 was marginally associated with clopidogrel active metabolite levels and ADP-stimulated platelet aggregation before (β = 1.57, P = 0.04 and β = −1.98, P = 0.01, respectively) but not after (β = 0.40, P = 0.59 and β = −0.13, P = 0.69, respectively) adjustment for the CYP2C19*2 variant. Stratified analyses of CYP2C19*2/CYP2C19*17 genotype combinations revealed that CYP2C19*2, and not CYP2C19*17, was the primary determinant in altering clopidogrel response.

Conclusions

Our results suggest that CYP2C19*17 has a small (if any) effect on clopidogrel-related traits and that the observed effect of this variant is due to LD with the CYP2C19*2 loss-of-function variant.

Ancillary